Nevirapine-selected mutations Y181I/C of HIV-1 reverse transcriptase confer cross-resistance to stavudine

Fausto Baldanti; Stefania Paolucci; Giovanni Maga; Nazzarena Labo; Ulrich Hübscher; Alexander Y. Skoblov; Lyubov Victorova; Silvio Spadari; Lorenzo Minoli; Giuseppe Gerna

doi:10.1097/00002030-200307040-00021

Nevirapine-selected mutations Y181I/C of HIV-1 reverse transcriptase confer cross-resistance to stavudine

Fausto Baldanti, Stefania Paolucci, Giovanni Maga, Nazzarena Labo, Ulrich Hübscher, Alexander Y. Skoblov, Lyubov Victorova, Silvio Spadari, Lorenzo Minoli, Giuseppe Gerna

IRCCS Fondazione Policlinico San Matteo

Research output: Contribution to journal › Article › peer-review

Abstract

Stavudine administration did not increase the frequency of Y181I/C reverse transcriptase (RT) mutations in non-nucleoside reverse transcriptase inhibitor (NNRTI)-treated patients. However, recombinant Y181C HIV-1 showed reduced stavudine susceptibility with respect to both recombinant wild-type and K103N HIV-1 strains. In addition, recombinant Y181I RT enzyme showed reduced susceptibility to stavudine with respect to both wild-type and K103N RT. A previously unnoticed role of Y181I/C RT changes selected by nevirapine or other NNRTI in determining stavudine resistance is documented.

Original language	English
Pages (from-to)	1568-1570
Number of pages	3
Journal	AIDS (London, England)
Volume	17
Issue number	10
DOIs	https://doi.org/10.1097/00002030-200307040-00021
Publication status	Published - Jul 4 2003

ASJC Scopus subject areas

Immunology
Immunology and Allergy

Access to Document

10.1097/00002030-200307040-00021

Cite this

Nevirapine-selected mutations Y181I/C of HIV-1 reverse transcriptase confer cross-resistance to stavudine. / Baldanti, Fausto ; Paolucci, Stefania; Maga, Giovanni; Labo, Nazzarena; Hübscher, Ulrich; Skoblov, Alexander Y.; Victorova, Lyubov; Spadari, Silvio; Minoli, Lorenzo; Gerna, Giuseppe.

In: AIDS (London, England), Vol. 17, No. 10, 04.07.2003, p. 1568-1570.

Research output: Contribution to journal › Article › peer-review

@article{cc4058d18ede4d05b59f5aa36c45a2d2,

title = "Nevirapine-selected mutations Y181I/C of HIV-1 reverse transcriptase confer cross-resistance to stavudine",

abstract = "Stavudine administration did not increase the frequency of Y181I/C reverse transcriptase (RT) mutations in non-nucleoside reverse transcriptase inhibitor (NNRTI)-treated patients. However, recombinant Y181C HIV-1 showed reduced stavudine susceptibility with respect to both recombinant wild-type and K103N HIV-1 strains. In addition, recombinant Y181I RT enzyme showed reduced susceptibility to stavudine with respect to both wild-type and K103N RT. A previously unnoticed role of Y181I/C RT changes selected by nevirapine or other NNRTI in determining stavudine resistance is documented.",

author = "Fausto Baldanti and Stefania Paolucci and Giovanni Maga and Nazzarena Labo and Ulrich H{\"u}bscher and Skoblov, {Alexander Y.} and Lyubov Victorova and Silvio Spadari and Lorenzo Minoli and Giuseppe Gerna",

year = "2003",

month = jul,

day = "4",

doi = "10.1097/00002030-200307040-00021",

language = "English",

volume = "17",

pages = "1568--1570",

journal = "AIDS",

issn = "0269-9370",

publisher = "NLM (Medline)",

number = "10",

}

TY - JOUR

T1 - Nevirapine-selected mutations Y181I/C of HIV-1 reverse transcriptase confer cross-resistance to stavudine

AU - Baldanti, Fausto

AU - Paolucci, Stefania

AU - Maga, Giovanni

AU - Labo, Nazzarena

AU - Hübscher, Ulrich

AU - Skoblov, Alexander Y.

AU - Victorova, Lyubov

AU - Spadari, Silvio

AU - Minoli, Lorenzo

AU - Gerna, Giuseppe

PY - 2003/7/4

Y1 - 2003/7/4

N2 - Stavudine administration did not increase the frequency of Y181I/C reverse transcriptase (RT) mutations in non-nucleoside reverse transcriptase inhibitor (NNRTI)-treated patients. However, recombinant Y181C HIV-1 showed reduced stavudine susceptibility with respect to both recombinant wild-type and K103N HIV-1 strains. In addition, recombinant Y181I RT enzyme showed reduced susceptibility to stavudine with respect to both wild-type and K103N RT. A previously unnoticed role of Y181I/C RT changes selected by nevirapine or other NNRTI in determining stavudine resistance is documented.

AB - Stavudine administration did not increase the frequency of Y181I/C reverse transcriptase (RT) mutations in non-nucleoside reverse transcriptase inhibitor (NNRTI)-treated patients. However, recombinant Y181C HIV-1 showed reduced stavudine susceptibility with respect to both recombinant wild-type and K103N HIV-1 strains. In addition, recombinant Y181I RT enzyme showed reduced susceptibility to stavudine with respect to both wild-type and K103N RT. A previously unnoticed role of Y181I/C RT changes selected by nevirapine or other NNRTI in determining stavudine resistance is documented.

UR - http://www.scopus.com/inward/record.url?scp=0041366954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041366954&partnerID=8YFLogxK

U2 - 10.1097/00002030-200307040-00021

DO - 10.1097/00002030-200307040-00021

M3 - Article

C2 - 12824799

AN - SCOPUS:0041366954

VL - 17

SP - 1568

EP - 1570

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 10

ER -

Nevirapine-selected mutations Y181I/C of HIV-1 reverse transcriptase confer cross-resistance to stavudine

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this